The drug aims to slow the advance of the neurodegenerative disease. Nearly all previous experimental drugs using the same approach have failed.

Cases were exploding in China well before the government's decision to abandon its strict "zero-COVID" policy, the director said, quashing suggestions that the sudden reversal caused a spike.